98%
921
2 minutes
20
Aim: To determine the utility and efficacy of a patient-reported history questionnaire to identify the presence of red flag symptoms indicative of lung cancer.
Materials And Methods: The study site introduced a paper-based screening questionnaire in 2019 to establish the presence of patient-reported red flag symptoms. This retrospective four-week (February 2020) single-centre observational study determined the prevalence of symptoms, compared referrer-reported to patient-reported clinical history, explored the relationship to the chest X-ray (CXR) outcome, and identified those diagnosed with lung cancer in the following two years. A parallel cross-sectional survey of CXR reporters was undertaken to identify the perceived value of the questionnaire in practice.
Results: 1874 CXRs were reviewed, with conflicting clinical history between referrer and patient evident. 1488 (83.4%) met the red flag criteria, confirming these to be over-sensitive. The diagnostic pathway, measured by the report turnaround time, was quicker for those meeting the red-flag criteria (P < .001), and significantly more likely to identify lung cancer (P < .005). 111 computed tomography (CT) scans were performed, with 17 primary lung cancers diagnosed. 10 additional lung cancers were identified in the following two-years. The majority of reporters utilised the screening questionnaire to aid decision-making.
Conclusion: Given the difficulty in early detection of lung cancers, utilising patient-reported clinical history can provide an opportunity to identify at-risk symptomatic patients, enable appropriate prioritisation of image reporting, and improve timely diagnosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.crad.2025.107034 | DOI Listing |
J Org Chem
September 2025
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, P. R. of China.
A Mg(OTf)-catalyzed asymmetric Michael addition/cyclization cascade reaction between 3-isothiocyanato oxindoles and 2-arylidene-1,3-indanediones has been developed. This transformation provides an efficient and concise approach to biologically important bispiro[indanedione-oxindole-pyrrolidinyl]s under mild conditions in good to excellent yields (70-99% yields) with moderate to good stereoselectivities (up to 99% and >95:5 d.r.
View Article and Find Full Text PDFClin Exp Immunol
September 2025
Rheumatology Department, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA , FHU CARE, Le Kremlin Bicêtre, France.
Introduction: Immunosenescence remodels immune functions and was first described with aging. It is present in 25% of cancer patients but has also been described in patients with Immune-mediated inflammatory diseases (IMIDs). This study aims at quantifying cells exhibiting a phenotype of senescence in CD4+ (T4sen) and CD8+ (T8sen) T cells, analyzing its potential drivers and the effect of anti-TNF treatment in a prospective cohort of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and Sjögren disease (SjD).
View Article and Find Full Text PDFZhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Urology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Objectives: Bladder cancer is a common malignancy with high incidence and poor prognosis. N-methyladenosine (mA) modification is widely involved in diverse physiological processes, among which the mA recognition protein YTH N-methyladenosine RNA binding protein F2 (YTHDF2) plays a crucial role in bladder cancer progression. This study aims to elucidate the molecular mechanism by which O-linked -acetylglucosamine (O-GlcNAc) modification of YTHDF2 regulates its downstream target, period circadian regulator 1 (), thereby promoting bladder cancer cell proliferation.
View Article and Find Full Text PDFZhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Geriatric Pulmonary and Critical Care Medicine, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Changsha 410008.
Objectives: Non-small cell lung cancer (NSCLC) is associated with poor prognosis, with 30% of patients diagnosed at an advanced stage. Mutations in the and genes are important prognostic factors for NSCLC, and targeted therapies can significantly improve survival in these patients. Although tissue biopsy remains the gold standard for detecting gene mutations, it has limitations, including invasiveness, sampling errors due to tumor heterogeneity, and poor reproducibility.
View Article and Find Full Text PDFHistol Histopathol
September 2025
Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Aims: We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer.
Methods: CD63 expression was analyzed immunohistochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence.